EUCTR2006-001012-68-GB进行中（未招募）不适用
A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular CarcinomaRevised Protocol Number 01, incorporating Amendment 02+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0 dated 29-Apr-06
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Signed written informed consent
- •Target population
- •2) Patient with diagnosis of hepatocellular carcinoma meeting the criteria below:
- •a) Biopsy-proven HCC (Histology or cytology)
- •b) Radiological evidence of HCC by contrast-enhanced CT scan or contrastenhanced MRI
- •i) Serology positive for Hepatitis B or C
- •ii) Alpha fetoprotein > 400 µg/L
- •3) Not appropriate for curative surgical resection.
- •4) Subjects who have received local therapy such as surgery, chemoembolization, radiation therapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible, provided that they either have a index lesion which has not been subjected to local therapy and/or the index lesion(s) within the field of the local therapy has shown an increase of = 25% in size. Local therapy must be completed at least 4 weeks prior to the baseline scan.
- •5) Measurable disease
- •All patients must have at least one previously un-irradiated, bi-dimensionally measurable lesion by CT or magnetic resonance imaging (MRI) scan of = 20 mm. Triphasic spiral CT or MRI scans are preferred when such equipment is available. All CT scans should employ a hepatoma protocol” image capture technique. The following are not considered measurable lesions:
- •a) Lesions seen on colonoscopy examination or barium studies
- •6) More than 4 weeks since surgery (with the exception of venous port access)
- •7) Cancer for the Liver Italian Program” Score (CLIP) = 3
- •a) No evidence of encephalopathy
- •8) ECOG performance status of 0, 1, 2
- •9) Adequate bone marrow function:
- •a) Absolute neutrophil count = 1500/mm3
- •b) Platelet count = 80,000/mm3
- •c) Hemoglobin = 9 g/dL
- •10) Adequate hepatic function:
- •a) Total bilirubin = 2.5 mg/dL
- •b) AST/ALT = 5 times the upper limit of normal (ULN)
- •c) Serum albumin > 2.8 g/dL
- •d) PT or INR = 1.8 times ULN
- •11) Adequate renal function:
- •a) Creatinine = 2.0 mg/dL, OR
- •b) Creatinine clearance = 45 mL/min based on Cockcroft formula
- •12) Screening blood pressure of < 150/100 mmHg
- •13) Left ventricular ejection fraction (LVEF) = 50%
- •Age and Sex
- •14) Men and women, ages 18 and older.
- •Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the study in such a manner that the risk of pregnancy is minimized.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Sex and Reproductive Status
- •1) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the study.
- •2) WOCBP not using an acceptable method of contraception sufficient to prevent pregnancy according to the instructions of the Principal Investigator.
- •3) Women who are pregnant or breastfeeding
- •4) Women with a positive blood serum pregnancy test on enrollment or prior to study drug administration.
- •Target Disease Exceptions
- •5) Exclude patients with CLIP score >3.
- •Medical History and Concurrent Diseases
- •6) Active bacterial infections, HIV/AIDS or other severe disease that would preclude study participation.
- •7) Gastrointestinal tract disease or prior surgery, resulting in an inability to take or absorb oral medication.
- •8) Other primary malignancy except carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer.
- •9) Mental incapacitation or psychiatric illness that would preclude study participation
- •10) Uncontrolled or significant cardiovascular disease including: myocardial infarction within 12 months, uncontrolled angina within 6 months, Class III-IV New York Heart Association (NYHA) congestive heart failure, grade 3 cardiac valve dysfunction
- •Physical and Laboratory Test Findings
- •11) Clinically significant ascites refractory to diuretic therapy
- •12) Presence of portal-systemic encephalopathy
- •13) Evidence of portal hypertension with bleeding esophageal or gastric varices within the past 2 months
- •a) Prior variceal bleed permitted if patient has undergone banding and there has been no evidence of bleeding for 2 months
- •14) Hyponatremia with sodium < 125 mEq/L
- •Allergies and Adverse Drug Reactions
- •15) History of allergy to BMS-582664 or related compounds.
- •Prohibited Therapies and/or Medications
- •16) Prior systemic therapy for HCC, including systemic chemotherapy, biological therapy, or hormone therapy.
- •17) Patients with previous thalidomide or anti-angiogenesis therapy
- •Other Exclusion Criteria
- •18) Prisoners or patients who are compulsorily detained
- •19) Subjects with a history of bleeding disorders and thrombosis, including portal vein thrombosis coagulopathy, and are on chronic anti-platelet therapy (aspirin > 300 mg/day, clopidrogel; patients entering trial on warfarin should have frequent monitoring of INR for at least the first month on study and may require longer monitoring to insure that degree of anticoagulation does not go outside the therapeutic range.)
- •20) Subjects with fibrolamellar disease
- •21) Subjects with portal-caval shunts
- •22) Subjects who are on a liver transplant list
- •23) Subjects who have any known history of known brain metastases. Should patient have any signs and symptoms of possible brain metastases, a CT/MRI of the brain should be conducted prior to enrollment as clinically indicated.
- •24) Subjects with hepatitis B DNA levels = 1,650 IU/ml using the Roche Taqman assay.
- •25) Subjects with centrally located cavitating lung lesions.
研究者
相似试验
进行中（未招募）
1 期
A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular CarcinomaRevised Protocol Number 01, incorporating Amendment 02+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0 dated 29-Apr-06EUCTR2006-001012-68-FRBristol-Myers Squibb International Corporation130
进行中（未招募）
1 期
Open-label, randomized study of two doses of GSK2857916 in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibodyRelapsed/Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-004810-25-ESGlaxoSmithKline, S.A.221
进行中（未招募）
1 期
Open-label, randomized study of two doses of GSK2857916 in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibodyRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-004810-25-GBGlaxoSmithKline Research & Development Ltd221
进行中（未招募）
1 期
Open-label, randomized study of two doses of GSK2857916 in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibodyRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-004810-25-DEGlaxoSmithKline Research & Development Ltd221
进行中（未招募）
1 期
Open-label, randomized study of two doses of GSK2857916 in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibodyRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-004810-25-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT221